Cardiology News / Recent Literature Review / Last Quarter 2021
Recent Cardiology Literature Review (Rhythmos 2022;17(1):107-114. )
27th Annual International AF Symposium, 13-15/1/22, New York, NY, USA
ACC.22, Washington, DC, USA, 2-4/4/22
EHRA 22, Copenhagen, Denmark, 3-5/4/22
HRS 22, San Francisco, CA, USA, 29/4-1/5/22
EuroPCR, Paris, France, 17-20/5/22
ESC Meeting, Barcelona, Spain, 26-29/8/2022
TCT 22, Boston, MA, USA, 16-20/9/22
Brugada Syndrome (BrS) is Associated With Increased Collagen Content Throughout Both Ventricles, With Maximal Collagen Proportions Observed Within BrS RVOT Epicardium
Evaluation of 28 whole hearts from consecutive sudden cardiac death cases attributed to BrS (75% men; median age of death 25 years, death occurred in sleep or at rest in 86%) and 29 hearts from a comparator group comprised of noncardiac deaths (control subjects), showed that the highest proportion of collagen was observed in the epicardial right ventricular outflow tract (RVOT) of the BrS group (23.7%). Ventricular myocardium from BrS decedents demonstrated a higher proportion of collagen compared with controls (ratio 1.45; P<0.001), with no significant interactions with respect to sampling location or tissue layer. There was insufficient evidence to support differences in collagen proportion in SCN5A-positive cases (n=5) vs control subjects (ratio 1.23; P=0.27) (Miles C et al, J Am Coll Cardiol 2021;78:1511–21).
XIENCE Short DAPT Program: Among High Bleeding Risk (HBR) Patients Undergoing PCI, 1-Month DAPT, Compared With 3-Month DAPT, Was Associated With Similar Ischemic Outcomes and Lower Bleeding Risk
Patients who received 1-month DAPT (XIENCE 28 USA and 28 Global; n=1392) were compared with those on 3-month DAPT (XIENCE 90; n= 1972) using propensity score stratification. The primary endpoint of all-cause mortality or myocardial infarction was similar between the 2 groups (7.3% vs 7.5%; P=0.41). The key secondary endpoint of BARC (Bleeding Academic Research Consortium) type 2-5 bleeding was lower with 1-month DAPT compared with 3-month DAPT (7.6% vs 10%; P=0.012). Major BARC type 3-5 bleeding did not differ at 12 months (3.6% vs 4.7%; P=0.082), but was lower with 1-month DAPT at 90 days (1.0% vs 2.1%; P=0.015) (Valgimigli M et al, J Am Coll Cardiol 2021;78:2060–2072).
A Booster (Third Dose) at Least 5 Months After a Second Dose of BNT162b2 Vaccine (Pfizer–BioNTech) Conferred 90% Lower Mortality Due to Covid-19 vs Those Who Did Not Receive a Booster
Among 843,208 participants 758,118 (90%) received the booster during the 54-day study period. Death due to Covid-19 occurred in 65 participants in the booster group (0.16 per 100,000 persons per day) and in 137 participants in the nonbooster group (2.98 per 100,000 persons per day). The adjusted hazard ratio–HR for death due to Covid-19 in the booster group, as compared with the nonbooster group, was 0.10 (P<0.001) (Arbel R et al, N Engl J Med 2021; 385:2413-2420)... (excerpt)
Authors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).